newsfilter
← Latest News
Business Wire·

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat